DR. DANIEL V SANTI, M.D., PH. D.
Hospitals at Belgrave Ave, San Francisco, CA

6759536, Jul 6, 2004

Aug 27, 2001

09/940316

Christopher Reeves - Orinda CA
Daniel Chu - Santa Clara CA
Chaitan Khosla - Palo Alto CA
Daniel Santi - San Francisco CA
Kai Wu - Foster City CA

Kosan Biosciences, Inc. - Hayward CA

C07D22118

546 71

Host cells comprising recombinant vectors encoding the FK-520 polyketide synthase and FK-520 modification enzymes can be used to produce the FK-520 polyketide. Recombinant DNA constructs comprising one or more FK-520 polyketide synthase domains, modules, open reading frames, and variants thereof can be used to produce recombinant polyketide synthases and a variety of different polyketides with application as pharmaceutical and veterinary products.

5492807, Feb 20, 1996

Nov 19, 1993

8/155943

Daniel V. Santi - San Francisco CA

C12Q 170

435 5

Antibodies are recovered and isolated from the sera of a number "n" of patients each of which have or have had the same given disease so that each of the "n" patients has, within a large number of different antibodies, some antibodies uniquely associated with the same disease of interest. The antibodies of a first patient are bound to a support surface. To carry out initial screening libraries of molecules are brought into contact with the bound antibodies of the first patient under conditions where binding will occur. Secondary screening is then carried out by extracting and labeling the antibodies of a second patient and using the labeled antibodies to probe the molecules (peptides) isolated in the initial screening. Many of the non-disease specific antibodies (of the second patient) will not bind to the molecules (peptides) of the isolated bacteriophage which bound to the antibodies of the first patient. Hence, the molecules (peptides) which are common to both patients with the same disease will be identified.

2009018, Jul 23, 2009

Jul 6, 2004

10/885305

Christopher Reeves - Orinda CA, US
Daniel Chu - Santa Clara CA, US
Chaitan Khosla - Palo Alto CA, US
Daniel Santi - San Francisco CA, US
Kai Wu - Foster City CA, US

C12P 21/04, C12N 15/11, C12P 17/16, C12N 1/21, C12N 15/00

435 691, 536 231, 4353201, 435118, 43525235

Host cells comprising recombinant vectors encoding the FK-520 polyketide synthase and FK-520 modification enzymes can be used to produce the FK-520 polyketide. Recombinant DNA constructs comprising one or more FK-520 polyketide synthase domains, modules, open reading frames, and variants thereof can be used to produce recombinant polyketide synthases and a variety of different polyketides with application as pharmaceutical and veterinary products.

6033883, Mar 7, 2000

Dec 11, 1997

8/989332

Philip J. Barr - Oakland CA
Daniel V. Santi - San Francisco CA
Gary W. Ashley - Alameda CA
Rainer Ziermann - San Mateo CA

KOSAN Biosciences, Inc. - Burlinggame CA

C12P 726, C12N 1554, C12N 1562, C12N 1581

435148

Hybrid and novel polyketide synthases and polyketides are produced by use of a multiple vector system. The combinatorial possibilities offered by placing the various catalytic activities of PKS systems on separate vectors permits the construction of improved libraries of PKS and polyketides. In addition, polyketides can be produced in hosts that ordinarily do not produce polyketides by supplying, along with an expression system for the desired PKS, an expression system for holo ACP synthase.

5164490, Nov 17, 1992

Nov 15, 1989

7/437511

Daniel V. Santi - San Francisco CA
Jeffrey Edman - San Francisco CA
Ursula Edman - San Francisco CA

The Regents of the University of California - Oakland CA

C07H 1512, C12P 2106, C12P 1936

536 27

Genetic material encoding dihydrofolate reductase (DHFR) of Pneumocystis carinii has been isolated and characterized. This genetic material allows the production of peptides for use in the design of inhibitors specific for P. carinii DHFR (as opposed to DHFR in the host infected with P. carinii) or can itself be directly used in hybridization assays.

2005028, Dec 29, 2005

Dec 21, 2004

11/019909

Daniel Santi - San Francisco CA, US
Robert McDaniel - Palo Alto CA, US
Li Tang - Foster City CA, US
Chaitan Khosla - Palo Alto CA, US

C12P019/62, C12N015/74, C12N001/21

435076000, 435252300, 435471000

Generic overproduction host cells can be used to produce any polyketide and obviate the need for performing conventional strain improvement.

RE39762, Aug 7, 2007

Dec 9, 2005

11/299244

Christopher Reeves - Orinda CA, US
Daniel Chu - Santa Clara CA, US
Chaitan Khosla - Palo Alto CA, US
Daniel Santi - San Francisco CA, US
Kai Wu - Foster City CA, US

Kosan Biosciences, Inc. - Hayward CA

C07D 515/00, C07D 498/00

546 92, 546 90

Polyketide compounds of the formula but not including FK-506, FK-520, 18-hydroxy-FK520 and 18-hydroxy-FK-506.

2003007, Apr 17, 2003

Sep 19, 2001

09/957483

Robert Arslanian - Pacifica CA, US
Gary Ashley - Alameda CA, US
Scott Frykman - Hayward CA, US
Bryan Julien - Oakland CA, US
Leonard Katz - Oakland CA, US
Chaitan Khosla - Palo Alto CA, US
Janice Lau - San Mateo CA, US
Peter Licari - Fremont CA, US
Rika Regentin - Hayward CA, US
Daniel Santi - San Francisco CA, US
Li Tang - Foster City CA, US

C12P017/00, C12P017/02, C07D417/02, C 07D 4 7/02

435/117000, 435/252300, 435/123000, 544/333000, 546/148000, 546/167000, 546/281700, 548/204000

Recombinant Myxococcus host cells can be used to produce polyketides, including epothilone and epothilone analogs that can be purified from the fermentation broth and crystallized.

7655808, Feb 2, 2010

Sep 30, 2008

12/241218

Steven D. Dong - San Francisco CA, US
Daniel V. Santi - San Francisco CA, US
David C. Myles - Kensington CA, US
Brian Hearn - San Francisco CA, US

Bristol-Myers Squibb Company - Princeton NJ

C07D 413/00, C07D 309/30

549293, 544149

Leptomycin-type compounds according to formula I.